The health insurer, currently trading at $235.39 with a market capitalization of $ ... aligning with Mizuho’s bullish outlook. Humana’s long-term growth strategy centers on margin recovery ...

The outcome of this litigation could have substantial implications for Humana’s future revenue and reimbursement rates. 2. Competitive pressures: The Medicare Advantage market remains highly ...

At the insurer's investor day, Humana struck a middle ground in defending the importance of the privatized Medicare program — ...

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside ...

The company has recently faced headwinds related to its star ratings, which play a crucial role in determining reimbursement rates and attracting customers in the competitive Medicare Advantage market ...

Investors long trusted UnitedHealth to deliver earnings beats, despite limited transparency. Now they want answers.

Blue Cross Blue Shield of Michigan is engaged in the most consequential reimbursement negotiations with hospitals in its ...

Humana's growth trajectory could rebound from current weakness, with management calling for pretax profits to more than double from 2025 to 2028 and grow in the low double digits in the long run at ...

Humana leaders asserted at the company’s investor day Monday that there’s still money to be made on Medicare Advantage ...